JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has reiterated a Market Outperform rating for Aquestive Therapeutics (NASDAQ:AQST) and maintained a $9 price target.
June 26, 2024 | 4:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating for Aquestive Therapeutics and maintained a $9 price target, indicating continued confidence in the company's performance.
The reiteration of a Market Outperform rating and the maintenance of a $9 price target by JMP Securities suggests strong confidence in Aquestive Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100